Meriofert Set

Human luteinising hormone (Human) and Follicle‑stimulating hormone, the active ingredients in Meriofert Set, are gonadotropins presented as an injectable solution for intramuscular and subcutaneous use. They are employed to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for biologic products.

Meriofert Set, a gonadotropin acting on the reproductive hormone pathway, is indicated for: - Infertility due to anovulation: stimulates follicular development to enable ovulation. - Controlled ovarian stimulation for assisted reproductive technologies: promotes multiple follicle growth for IVF cycles. - Induction of ovulation in women with luteinising hormone deficiency: replaces deficient LH to trigger ovulation.

Adverse reactions reported with Meriofert Set are generally related to its hormonal activity and injection site.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Headache. - Nausea. - Transient ovarian hyperstimulation (mild).

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe). - Multiple pregnancy. - Allergic reaction or anaphylaxis. - Thromboembolic events. - Ectopic pregnancy.

Before initiating therapy, clinicians should consider the following precautions: - Baseline ovarian assessment: perform ultrasound to evaluate follicular status. - Hormone monitoring: regularly measure estradiol levels during treatment. - Hypersensitivity: avoid in patients with known allergy to the product or its excipients. - Ovarian cysts: use caution in women with existing ovarian cysts. - Thyroid disease: assess thyroid function as gonadotropin response may be altered. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other medications that affect ovarian response or coagulation.

Major Interactions (Avoid): - Concurrent use of other gonadotropins: increases risk of severe ovarian hyperstimulation. - High‑dose estrogen therapy: may blunt the intended ovulatory response.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for thrombotic complications. - Corticosteroids: may alter hormonal dynamics, requiring dose adjustment. - Thyroid hormone replacement: ensure euthyroid status to optimise response.